Mosapramin

Mosapramin
(IUPAC) ime
	1'-[3-(3-hloro-10,11-dihidro-5H-dibenzo[b,f]azepin-5-il)propil]hexahidro-2H-spiro[imidazo[1,2-a]piridin-3,4'-piperidin]-2-on
Klinički podaci
AHFS/Drugs.com	Internacionalno ime leka
Identifikatori
CAS broj	89419-40-9
ATC kod	N05AX10
PubChem	4257
UNII	04UZQ7O9SJ
KEGG	D08235
Hemijski podaci
Formula	C28H35ClN4O
Mol. masa	479.057 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C28H35ClN4O/c29-23-12-11-22-10-9-21-6-1-2-7-24(21)32(25(22)20-23)16-5-15-31-18-13-28(14-19-31)27(34)30-26-8-3-4-17-33(26)28/h1-2,6-7,11-12,20,26H,3-5,8-10,13-19H2,(H,30,34) ; Key: PXUIZULXJVRBPC-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	℞ Prescription only
Način primene	Oralno

Mosapramin (Kremin) je atipični antipsihotik koji se koristi u Japanu.^[4] On je potentan dopaminski antagonist sa visokim afinitetom za D₂, D₃, i D₄ receptore,^[5] i sa umerenim afinitetom za 5-HT₂ receptore.^[6]

Reference[uredi | uredi kod]

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Takahashi N, Terao T, Oga T, Okada M. Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia. Neuropsychobiology. 1999;39(2):81-5. PMID 10072664
↑ Futamura T, Ohashi Y, Yano K, Takahashi Y, Haga K, Fukuda T. The affinities of mosapramine for the dopamine receptor subtypes in human cell lines expressing D2, D3 and D4 receptors. Nippon Yakurigaku Zasshi. (Japanese) 1996 May;107(5):247-53. PMID 8690306
↑ Sumiyoshi T, Suzuki K, Sakamoto H, Yamaguchi N, Mori H, Shiba K, Yokogawa K. Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy. Neuropsychopharmacology. 1995 Feb;12(1):57-64. DOI:10.1016/0893-133X(94)00064-7 PMID 7766287

	Portal Medicina
	Portal Hemija